7.3 Consent Documentation, Special Circumstances and Updates
Key Takeaways
Paper or electronic signed and dated consent can be appropriate under the approved process.
An impartial witness is needed for the applicable unable-to-read consent process.
New information affecting willingness to continue should be communicated in a timely way.
Consent Documentation, Special Circumstances and Updates
When a participant (or LAR) is unable to read or write:
- An impartial witness (an individual independent of the trial, who cannot be unfairly influenced by people involved with the trial) must be present during the entire informed consent discussion.
- The written ICF and any other written information is read aloud and explained to the subject.
- The subject orally consents and, if physically able, signs or makes their mark (e.g., a thumbprint) on the ICF.
- The impartial witness must personally sign and date the consent form, attesting that the information in the ICF was accurately explained to, and apparently understood by, the subject, and that consent was freely given.
- The person obtaining consent also personally signs and dates the document.
Language, capacity and electronic approaches
Use consent materials and discussion understandable to the participant. Plan appropriate translation and interpreter support; verify the approved language/version and any required certification. The ECO includes a task to facilitate and verify certification of translations. Back-translation is a possible quality method, not a universal ICH requirement. A witness for inability to read is distinct from an interpreter for a language difference.
Where a minor is enrolled, provide age-appropriate information and seek assent as appropriate under the reviewed process and applicable requirements. The number of parents whose permission is needed depends on local rules and the study, not a universal ICH age/risk table. Plan for consent if the participant reaches legal consent age during the trial. Likewise, reassess consent when someone enrolled through a representative gains capacity.
Paper or electronic documentation and remote discussions can be appropriate. Confirm identity, opportunity for questions, privacy, access to the materials and a copy of the signed and dated form. Personally executed electronic dates and signatures can be valid; a handwritten date is not the only acceptable format. Do not use electronic convenience to bypass comprehension or the approved consent process.
Regulatory Re-Consent Triggers
Informed consent is never a closed event. Whenever trial conditions change, investigators must determine whether active participants must be re-consented:
| Re-Consent Trigger | Underlying Rationale | Required Action & Timeline |
|---|---|---|
| Protocol Amendments | New procedures, increased blood draw volumes, modified visit schedules, or changes to treatment dosage. | IRB approves revised ICF; active participants re-consent according to the approved implementation plan, before affected procedures. |
| New Safety Information | Updated Investigator's Brochure, newly identified adverse drug reactions, or regulatory black-box warnings. | Communicate relevant new information promptly; obtain applicable approval for revised materials and document updated consent under the reviewed implementation process. |
| Minor Reaching Age of Majority | Pediatric participant turns 18 (or jurisdictional legal adult age) while active in the study. | the appropriate consent process should be implemented under applicable requirements; subject must be re-consented as an autonomous adult using the adult ICF before continued activities as required by the approved process. |
| Cognitive Capacity Recovery | Participant who was enrolled via LAR (e.g., comatose stroke patient) regains full decision-making capacity. | the applicable consent/representation arrangement should be reassessed; participant must be formally consented using the standard ICF to continue participation. |
| Study Duration Extension | Significant extension of trial follow-up period altering participant commitment. | Revised ICF reflecting extended timeline approved by IRB and signed by participants. |
CRA Source Data Verification (SDV) for Informed Consent
Consent is a critical process. The CRA verifies it according to the justified monitoring plan; ICH does not prescribe a universal 100% SDV rate. The CRA audits against the 5-Point Consent Verification Protocol:
Warning
Consent Must Precede All Protocol Procedures: Under ICH E6(R3), under the standard consent process, consent should be obtained and documented before trial participation and applicable research procedures. This includes protocol-mandated screening lab panels, diagnostic imaging, and especially washout periods where prescribed standard-of-care medications are discontinued. Taking a patient off an antihypertensive drug to prepare for a screening visit without a signed consent form is a major GCP violation that severely compromises subject safety.
Tip
CRA Red Flag Detection: When auditing consent forms, beware of "convenience dating" where the study coordinator writes the date next to the participant's signature. Both FDA investigators and GCP auditors scrutinize handwriting: if the date beside the participant's signature matches the coordinator's handwriting style, it is cited as an audit finding. Participants should personally execute the required signature and date using the approved paper or electronic process.
Standard chronology and prospectively reviewed exceptions
Compare actual consent timing with the first research activity, including a protocol-directed medication change, rather than checking only whether the dates match. A routine clinical test performed for care before research involvement is a different situation from a new research screening procedure. Establish the purpose and authorised process from evidence.
E6(R3) recognises carefully defined emergency circumstances where prior participant or representative consent is not possible. These require the appropriate prospectively reviewed protocol and safeguards under applicable requirements. An investigator cannot create a blanket exception merely because a patient presents urgently. Verify the approved process and subsequent information/consent requirements rather than applying either an unrestricted emergency waiver or an unexplained absolute rule.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1, WMA Declaration of Helsinki, 2024, ICH E11(R1).
A person understands the discussion but cannot read the materials. Which safeguard applies?
Have the investigator sign the participant’s name.
Use the approved process with an impartial witness throughout the discussion and appropriate documentation.
Automatically appoint a representative because inability to read proves incapacity.
Exclude the person solely because of literacy.
Sections you finish are checked off in the contents.